Sarepta Soars on Expanded Approval for Muscular Dystrophy Drug

Sarepta Therapeutics' gene therapy received expanded US approval to include more children with a deadly muscle disease. The treatment’s approval was widened for use in patients who are at least 4 years old with Duchenne muscular dystrophy. Natalia Kniazhevich has more.

--------
More on Bloomberg Television and Markets


Connect with Bloomberg Television on:

Connect with Bloomberg Business on:

More from Bloomberg:


Watch more on YouTube:

[michaelmcwhirter]

I heard they've been fighting for approval these past years and finally got it